Multiple sclerosis health-related quality of life utility values from the UK MS register

• Published in: Multiple sclerosis journal - experimental, translational and clinical Vol. 9; no. 2; p. 20552173231178441
• Main Authors: Heather, A, Goodwin, E, Green, C, Morrish, N, Ukoumunne, OC, Middleton, RM, Hawton, A
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01-04-2023; Sage Publications Ltd
• Subjects: Cost analysis; Multiple sclerosis; Original; Quality of life; United Kingdom > UK; Multiple sclerosis; cost-benefit analysis; technology assessment; United Kingdom; quality of life; patient-reported outcome measures; biomedical
• ISSN: 2055-2173; 2055-2173
• DOI: 10.1177/20552173231178441

Background
New interventions for multiple sclerosis (MS) commonly require a demonstration of cost-effectiveness using health-related quality of life (HRQoL) utility values. The EQ-5D is the utility measure approved for use in the UK NHS funding decision-making. There are also MS-specific utility measures – e.g., MS Impact Scale Eight Dimensions (MSIS-8D) and MSIS-8D-Patient (MSIS-8D-P).
Objectives
Provide EQ-5D, MSIS-8D and MSIS-8D-P utility values from a large UK MS cohort and investigate their association with demographic/clinical characteristics.
Methods
UK MS Register data from 14,385 respondents (2011 to 2019) were analysed descriptively and using multivariable linear regression, with self-report Expanded Disability Status Scale (EDSS) scores.
Results
The EQ-5D and MSIS-8D were both sensitive to differences in demographic/clinical characteristics. An inconsistency found in previous studies whereby mean EQ-5D values were higher for an EDSS score of 4 rather than 3 was not observed. Similar utility values were observed between MS types at each EDSS score. Regression showed EDSS score and age were associated with utility values from all three measures.
Conclusions
This study provides generic and MS-specific utility values for a large UK MS sample, with the potential for use in cost-effectiveness analyses of treatments for MS.